Publications by authors named "Carol Franks"

Claim this Profile
A
A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Jocelyn H Leu, Xin Miao, Kevin Shalayda, Kevin J Coe, Ariane Kahnt, Carol Franks

Clin Pharmacol Drug Dev· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.
Kristen Sweet, Qingxuan Song, Matthew J Loza, Iain B McInnes, Keying Ma, Carol Franks

RMD Open· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
Matteo Cesaroni, Loqmane Seridi, Matthew J Loza, Jessica Schreiter, Kristen Sweet, Carol Franks

Arthritis Rheumatol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Mark C Genovese, Elizabeth Hsia, Stanley M Belkowski, Caly Chien, Tara Masterson, Carol Franks

J Rheumatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Carl L Manthey, Dana L Johnson, Carl R Illig, Robert W Tuman, Zhao Zhou, Carol F Franks

Mol Cancer Ther· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Daniel J Parks, Louis V LaFrance, Raul R Calvo, Karen L Milkiewicz, Juan José Marugán, Carol F Franks

Bioorg Med Chem Lett· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Holly K Koblish, Shuyuan Zhao, Carol F Franks, Robert R Donatelli, Rose M Tominovich

Mol Cancer Ther· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
Bruce L Grasberger, Tianbao Lu, Carsten Schubert, Daniel J Parks, Theodore E Carver, Carol F Franks

J Med Chem· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis